Sarepta Therapeutics' (SRPT) stock is climbing after Vertex Pharmaceuticals (VRTX) included in-depth information about Sarepta's treatment for Duchenne Muscular Dystrophy, or DMD, in a slide presentation. In the slide presentation, which was posted online, Vertex describes how Sarepta's treatment, called Eteplirsen, works. The drug has "demonstrated a broadly favorable safety and tolerability profile and restoration of dystrophin protein expression," Vertex added. Although a number of drugs made by several other companies are mentioned by Vertex on a previous slide, the information provided about Sarepta's treatment is far more comprehensive than the details provided for the alternative drugs. This development led to speculation among some investors that Vertex could be interested in buying rights to the treatment outside of North America from Sarepta. In late morning trading, Sarepta rose 61c, or 2.12%, to $29.36.
- Pharmaceuticals & Drug Trials
- Vertex Pharmaceuticals